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Abstract
Objectives
To investigate the epidemiology of herpes simplex virus type 1 (HSV-1) in Latin America
and the Caribbean.
Methods
Systematic review and meta-analytics guided by the Cochrane Collaboration Handbook and
reported following the PRISMA guidelines.
Results
Thirty-three relevant reports were identified including 35 overall (and 95 stratified) seroprev-
alence measures, and five and nine proportions of virus isolation in genital ulcer disease
(GUD) and in genital herpes, respectively. Pooled mean seroprevalence was 57.2% (95%
CI: 49.7–64.6%) among children and 88.4% (95% CI: 85.2–91.2%) among adults. Pooled
mean seroprevalence was lowest at 49.7% (95% CI: 42.8–56.6%) in those aged�10, fol-
lowed by 77.8% (95% CI: 67.9–84.8%) in those aged 10–20, 82.8% (95% CI: 73.1–90.8%)
in those aged 20–30, 92.5% (95% CI: 89.4–95.1%) in those aged 30–40, and 94.2% (95%
CI: 92.7–95.5%) in those aged�40. Age was the strongest source of heterogeneity in sero-
prevalence, explaining 54% of variation. Evidence was found for seroprevalence decline
over time. Pooled mean proportion of HSV-1 isolation was 0.9% (95% CI: 0.0–3.6%) in
GUD and 10.9% (95% CI: 4.4–19.4%) in genital herpes.
Conclusions
HSV-1 is a widely prevalent infection in this region, but its epidemiology may be slowly tran-
sitioning, with still limited contribution for HSV-1 in genital herpes.
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Introduction
Infection with herpes simplex virus type 1 (HSV-1) is prevalent globally [1]. HSV-1 is respon-
sible for a range of mild to serious morbidities [2, 3], with its typical clinical manifestation
being orolabial herpes lesions [2, 4]. The infection, lifelong and mostly asymptomatic, is usu-
ally acquired orally and in childhood [3]. However, mounting evidence suggests an HSV-1 epi-
demiological transition in Europe and North America [4–7] and in Asia [8], associated with
decreasing oral acquisition in childhood and increasing sexual acquisition (through oral sex)
in adulthood [4–6]. In multiple Western countries, HSV-1 is already the primary cause of first
episode genital herpes, surpassing the role of that of HSV-2 [4, 5, 7, 9–11]. An epidemiological
transition is defined here as a significant change in the occurrence of the infection and/or its
mode of transmission patterns.
HSV-1 infection is of growing interest and a focus of an international multi-sectorial effort,
guided by the World Health Organization, to develop a vaccine to control infection transmis-
sion [12, 13]. To inform these global health efforts, we aimed in the present study to provide a
detailed investigation of the epidemiology of HSV-1 in Latin America and the Caribbean, by
conducting a comprehensive systematic review and a range of meta-analytics. Importantly, we
estimated HSV-1 antibody prevalence (seroprevalence), its associations and temporal trend,
and assessed the role of HSV-1 as a cause of clinically-diagnosed genital ulcer disease (GUD)
and clinically-diagnosed genital herpes.
Material and methods
The methodology of this study was adapted from that of a study investigating HSV-1 epidemi-
ology in Asia [8].
Data sources and search strategy
The systematic review and meta-analyses were guided by the Cochrane collaboration Hand-
book [14], and were reported following the Preferred Reporting Items for Systematic Reviews
and Meta-analyses (PRISMA) guidelines (checklist in S1 Table) [15]. PubMed, Embase, and
LILACS databases were systematically searched up to September 12, 2018. The search strate-
gies included MeSH/Emtree and broad terms with no language or year restrictions (S2 Table).
The definition for the Latin America and the Caribbean region included 46 countries, as listed
in S1 Box.
Study selection and inclusion and exclusion criteria
Search results were de-duplicated using a reference manager, Endnote (Thomson Reuters,
USA). Titles and abstracts were screened for relevant and potentially relevant reports, and the
full-texts of these relevant or potentially relevant reports were retrieved for further screening.
Bibliographies of identified relevant reports and reviews were also screened for additional
potentially relevant reports. Initial screening was conducted by LS and MA, and double
screening was conducted by MH.
Reports met the inclusion criteria if they reported primary data on any of three outcome
measures: 1) HSV-1 seroprevalence based on a valid diagnostic method (i.e. strictly type-spe-
cific glycoprotein-G based assays), 2) proportion of HSV-1 virus isolation in clinically-diag-
nosed GUD, or 3) proportion of HSV-1 virus isolation in clinically-diagnosed genital herpes.
Only measures with a sample size�10 were included. Case reports, editorials, letters to edi-
tors, commentaries, and reviews were excluded. HSV-1 seroprevalence measures among
HSV-1 epidemiology in Latin America and Caribbean
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newborns<3 months of age were excluded, as they may reflect maternal antibodies as opposed
to current infection.
In this systematic review, a “report” denotes a publication reporting a relevant outcome
measure, while a “study” denotes the extracted details of an outcome measure.
Data extraction and synthesis
Relevant reports were extracted by LS and MA, and double-extracted by MH. Extracted data
included publication details, population characteristics, study methodology characteristics,
and outcome measures. The extracted variables are listed in S2 Box. Extracted overall outcome
measures for the full sample were replaced by stratified measures (if available), based on a pre-
defined protocol for the stratification hierarchy, provided that the sample size in each stratum
was�10.
For HSV-1 seroprevalence measures, extracted strata were prioritized for population type
(Fig 1), followed by age bracket (children (�15 years of age) versus adults (>15 years of age)),
and age group (�10, 10–20, 20–30, 30–40, and�40 years of age). These age ranges were
informed by the actually available age strata in extracted studies. For the proportions of HSV-1
virus isolation in GUD or in genital herpes, the stratification hierarchy included primary ver-
sus recurrent episode, followed by study site (hospital versus sexually transmitted infection
clinic).
Quality assessment
Given the documented limitations in the sensitivity and specificity of HSV-1 serology diagnos-
tic assays [16, 17], the validity of the type-specific diagnostic method of each study was investi-
gated and determined in consultation with an expert advisor in HSV-1 serology, Professor
Rhoda Ashley-Morrow, University of Washington, Seattle. Studies where the validity of the
diagnostic method could not be confirmed, were excluded from the systematic review and
meta-analytics.
Informed by the Cochrane approach [14], studies with valid assays were further classified
into low versus high precision based on the number of individuals tested for HSV-1 in that
study (<100 versus�100). Moreover, studies were classified into low versus high risk of bias
(ROB) using two quality domains: sampling method (probability-based versus non-
Fig 1. Population type definition and classification. Abbreviation: HSV-1 = Herpes simplex virus type 1.
https://doi.org/10.1371/journal.pone.0215487.g001
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probability-based sampling) and response rate (�80% versus<80%). Studies with no informa-
tion on a quality domain were classified as having an “unclear” ROB for that domain.
Precision and ROB domains were included in the meta-regression analyses (as described
below), to examine their associations with seroprevalence, that is the influence of the charac-
teristics of the study methodology on observed HSV-1 seroprevalence.
Meta-analyses
Pooled means were estimated for HSV-1 seroprevalence and its relevant strata by population
type, age bracket, age group, and year of publication category (<2000, 2000–2009, and 2010–
2018), as well as for the proportions of HSV-1 virus isolation in GUD and in genital herpes,
whenever�3 measures were available. The estimates were calculated in R version 3.4.1 [18]
using a DerSimonian-Laird random-effects model [19], as applied in the meta package [20].
The Freeman-Tukey type arcsine square-root transformation [21] was utilized to stabilize the
variance of each included measure. Forest plots were produced to visualise estimates and their
95% confidence intervals (CIs).
Heterogeneity was assessed using three complementary metrics: 1) Cochrane Q statistics to
test for existence of heterogeneity [19, 22], 2) I2 to provide the magnitude of heterogeneity that
is explained by true differences in the outcome measures across studies (as opposed to being
due to sampling variation) [19, 23], and 3) prediction interval to provide the range of true
effect sizes of the outcome measures around the pooled mean [19, 23].
Meta-regressions
Associations with HSV-1 seroprevalence and sources of between-study heterogeneity were
investigated using univariable and multivariable random-effects meta-regression analyses.
Independent variables with a p-value�0.1 in univariable analysis were included in the multi-
variable analyses. In the multivariable models, a p-value of�0.05 for any given independent
variable indicated strong evidence for an association with HSV-1 seroprevalence.
The included independent variables were set a priori and consisted of: age bracket, age
group, sex, population type, country’s income, assay type (Western blot, enzyme-linked
immunosorbent assay, and others), sample size (<100 versus�100), sampling method (non-
probability-based versus probability-based), response rate (�80 versus otherwise), year of pub-
lication category, year of data collection, and year of publication.
The variable of country’s income (for countries with available data and per World Bank
classification [24]) categorized the countries into upper-middle-income countries (Brazil,
Colombia, Costa Rica, Jamaica, Mexico, and Peru), high-income countries (Barbados, Chile,
and Argentina), and “mixed” for studies including different countries in the study sample.
Missing values for the year of data collection were imputed utilizing data for the year of
publication as adjusted by the median difference between year of publication and year of data
collection (for studies with non-missing data).
The meta-regressions were conducted on the log-transformed proportions (with inverse-
variance weighting) in Stata/SE version 13 [25], using the metareg package [26].
Results
Search results and scope of evidence
Fig 2 details the study selection process per PRISMA guidelines [15]. The search identified
4,023 citations (PubMed: 847, Embase: 1,329, and LILACS 1,847) of which duplicates were
HSV-1 epidemiology in Latin America and Caribbean
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removed. Title and abstract screening yielded 367 relevant and potentially relevant reports.
Full-text screening of these latter reports identified 29 reports that met the inclusion criteria.
Four additional relevant reports [27–30] were identified through bibliography screening of
reviews and relevant reports.
Fig 2. Flow chart of article selection for the systematic review of HSV-1 infection in Latin America and the
Caribbean, per the PRISMA guidelines [15]. Abbreviation: HSV-1 = Herpes simplex virus type 1.
https://doi.org/10.1371/journal.pone.0215487.g002
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Extracted measures included: 35 overall HSV-1 seroprevalence measures yielding 95 strati-
fied seroprevalence measures, five proportions of viral HSV-1 isolation in GUD, and nine pro-
portions of viral HSV-1 isolation in genital herpes. No HSV-1 seroprevalence measure was
identified among clinical children populations.
Overview of HSV-1 seroprevalence
Table 1 lists the extracted stratified HSV-1 seroprevalence measures and their characteristics
(number of measures (n) = 95). Most measures were from studies conducted prior to 2010
(n = 76; 80.0%), and were based on convenience samples (n = 68; 71.0%). Seroprevalence
across all measures ranged between 7.7–100% with a median of 86.0% (n = 95; Table 2).
HSV-1 seroprevalence ranged between 7.7–92.0% with a median of 55.1% among healthy
children populations (n = 19), between 38.3–98.9% with a median of 87.6% among healthy
adult populations (n = 51), and between 74.4–100% with a median of 91.5% among clinical
adult populations (n = 7). Table 2 lists summaries for other population categories.
Pooled mean estimates for HSV-1 seroprevalence
Table 2 displays the results of the meta-analyses. The overall pooled mean HSV-1 seropreva-
lence (n = 95) was 83.1% (95% CI: 79.2–86.5%).
The pooled mean HSV-1 seroprevalence was 57.2% (95% CI: 49.7–64.6%) among healthy
children populations, 84.5% (95% CI: 79.9–88.5%) among healthy adult populations, and
90.9% (95% CI: 84.2–95.9%) among clinical adult populations.
The pooled mean seroprevalence increased with age. It was lowest at 49.7% (n = 14; 95%
CI: 42.8–56.6%) in those aged�10, followed by 77.8% (n = 17; 95% CI: 67.9–84.8%) in those
aged 10–20, 82.8% (n = 12; 95% CI: 73.1–90.8%) in those aged 20–30, 92.5% (n = 9; 95% CI:
89.4–95.1%) in those aged 30–40, and 94.2% (n = 11; 95% CI: 92.7–95.5%) in those aged�40.
The pooled mean seroprevalence decreased with time. It was highest at 90.8 (95% CI: 85.8–
94.9%) before the year 2000, followed by 80.7% (95% CI: 73.6–87.0%) in 2000–2009, and
78.8% (95% CI: 72.7–84.3) in 2010–2018.
Forest plots for all adult populations and all children populations can be found in S1 Fig.
All meta-analyses showed evidence of heterogeneity (Table 2). Heterogeneity was attributed to
true variability in seroprevalence across studies rather than chance (Table 2). The heterogene-
ity was affirmed by the wide prediction intervals (Table 2).
Predictors of HSV-1 seroprevalence
Table 3 and S3 Table display the results of the univariable and multivariable analyses. In the
univariable analyses, age bracket, age group, sex, population type, year of publication category,
year of data collection, and year of publication qualified to be included in the multivariable
analysis (p<0.1). Country’s income, assay type, response rate, sample size, and sampling
method all had a p-value >0.1, and hence, were not included in the multivariable analyses.
Since age bracket and age group are variables that are not independent of each other, two
multivariable models were analyzed, each using one of these variables. For a similar consider-
ation, the year of publication was included in the multivariable analyses, instead of year of data
collection, given its more complete data. As for the multivariable analyses including the year of
publication category, instead of the linear year of publication term, the results can be found in
S3 Table.
The first model included age bracket, sex, population type, and year of publication. It
explained 42.82% of the seroprevalence variation. In adults, seroprevalence was 1.39-fold (95%
CI: 1.24–1.57) higher than that in children.
HSV-1 epidemiology in Latin America and Caribbean
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Table 1. Studies reporting HSV-1 seroprevalence in Latin America and the Caribbean.
Author, year Year(s) of
data
collection
Country Study site Study
design
Sampling
method
Population HSV-1
serological
assay
Sample
size
HSV-1
seroprevalence (%)
Healthy children populations
(n = 19)
Clemens, 2010
[43]
1996–97 Brazil Community CS RS 1–5 years old boys ELISA 52 44.2
Clemens, 2010
[43]
1996–97 Brazil Community CS RS 6–10 years old boys ELISA 49 55.1
Clemens, 2010
[43]
1996–97 Brazil Community CS RS 11–15 years old boys ELISA 125 65.6
Clemens, 2010
[43]
1996–97 Brazil Community CS RS 1–5 years old girls ELISA 47 38.3
Clemens, 2010
[43]
1996–97 Brazil Community CS RS 6–10 years old girls ELISA 50 58.0
Clemens, 2010
[43]
1996–97 Brazil Community CS RS 11–15 years old girls ELISA 126 74.6
Conde-Glez,
2013 [44]
2005–06 Mexico Community CS RS 1–9 years old girls ELISA 252 51.0
Conde-Glez,
2013 [44]
2005–06 Mexico Community CS RS 1–9 years old boys ELISA 264 50.0
Cowan, 2003
[45]
- Brazil Outpatient
clinic
CS Conv 1–4 years old
children
ELISA 232a 36.0
Cowan, 2003
[45]
- Brazil Outpatient
clinic
CS Conv 5–9 years old
children
ELISA 232a 52.4
Cowan, 2003
[45]
- Brazil Outpatient
clinic
CS Conv 10–14 years old
children
ELISA 233a 68.1
De Salles-
Gomes, 1981
[46]
1980 Brazil Outpatient
clinic
CS Conv 7–11 month babies IF 13 7.7
De Salles-
Gomes, 1981
[46]
1980 Brazil Outpatient
clinic
CS Conv 1–4 years old
children
IF 50 38.0
De Salles-
Gomes, 1981
[46]
1980 Brazil Outpatient
clinic
CS Conv 5–9 years old
children
IF 50 64.0
De Salles-
Gomes, 1981
[46]
1980 Brazil Outpatient
clinic
CS Conv 10–14 years old
children
IF 50 92.0
Robinson, 2002
[47]
- Multiple
countries in
South America
Community CS Conv �3 years old
children
WB 23 29.0
Robinson, 2002
[47]
- Multiple
countries in
South America
Community CS Conv 4–6 years old
children
WB 56 72.0
Robinson, 2002
[47]
- Multiple
countries in
South America
Community CS Conv 7–9 years old
children
WB 68 76.0
Robinson, 2002
[47]
- Multiple
countries in
South America
Community CS Conv 10–13 years old
children
WB 54 81.0
Healthy adult populations
(n = 51)
Arriaga-
Demeza, 2008
[48]
2002–03 Mexico Community CS Conv 18–20 years old
females
WB 195 50.3
(Continued)
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Table 1. (Continued)
Author, year Year(s) of
data
collection
Country Study site Study
design
Sampling
method
Population HSV-1
serological
assay
Sample
size
HSV-1
seroprevalence (%)
Arriaga-
Demeza, 2008
[48]
2002–03 Mexico Community CS Conv 21–25 years old
females
WB 153 53.6
Arriaga-
Demeza, 2008
[48]
2002–03 Mexico Community CS Conv �26 years old
females
WB 31 74.2
Arriaga-
Demeza, 2008
[48]
2002–03 Mexico Community CS Conv 18–20 years old
males
WB 103 46.6
Arriaga-
Demeza, 2008
[48]
2002–03 Mexico Community CS Conv 21–25 years old
males
WB 102 61.8
Arriaga-
Demeza, 2008
[48]
2002–03 Mexico Community CS Conv �26 years old males WB 18 55.6
Morrow, 2014
[16]
2000–01 Argentina Community CS Conv Argentinian women WB 99 98.9
Morrow, 2014
[16]
2000–01 Costa Rica Community CS Conv Costa Rican women WB 98 92.9
Morrow, 2014
[16]
2000–01 Mexico Community CS Conv Mexican women WB 100 98.0
Clemens, 2010
[43]
1996–97 Brazil Community CS RS 16–20 years old
males
ELISA 119 69.8
Clemens, 2010
[43]
1996–97 Brazil Community CS RS 21–30 years old
males
ELISA 107 76.6
Clemens, 2010
[43]
1996–97 Brazil Community CS RS 31–40 years old
males
ELISA 78 85.9
Clemens, 2010
[43]
1996–97 Brazil Community CS RS 16–20 years old
females
ELISA 128 75.8
Clemens, 2010
[43]
1996–97 Brazil Community CS RS 21–30 years old
females
ELISA 126 81.0
Clemens, 2010
[43]
1996–97 Brazil Community CS RS 31–40 years old
females
ELISA 82 81.7
Conde-Glez,
2013 [44]
2005–06 Mexico Community CS RS 20–29 years old
females
ELISA 252a 78.0
Conde-Glez,
2013 [44]
2005–06 Mexico Community CS RS 30–39 years old
females
ELISA 252a 96.0
Conde-Glez,
2013 [44]
2005–06 Mexico Community CS RS 40–49 years old
female
ELISA 252a 91.0
Conde-Glez,
2013 [44]
2005–06 Mexico Community CS RS 50–59 years old
females
ELISA 252a 98.0
Conde-Glez,
2013 [44]
2005–06 Mexico Community CS RS �60 years old
females
ELISA 252a 95.0
Conde-Glez,
2013 [44]
2005–06 Mexico Community CS RS 20–29 years old
males
ELISA 264a 91.0
Conde-Glez,
2013 [44]
2005–06 Mexico Community CS RS 30–39 years old
males
ELISA 264a 91.0
Conde-Glez,
2013 [44]
2005–06 Mexico Community CS RS 40–49 years old male ELISA 264a 93.0
Conde-Glez,
2013 [44]
2005–06 Mexico Community CS RS 50–59 years old
males
ELISA 264a 95.0
Conde-Glez,
2013 [44]
2005–06 Mexico Community CS RS �60 years old males ELISA 264a 94.0
(Continued)
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Table 1. (Continued)
Author, year Year(s) of
data
collection
Country Study site Study
design
Sampling
method
Population HSV-1
serological
assay
Sample
size
HSV-1
seroprevalence (%)
Corona, 2010
[28]
2002–05 Mexico Community CS Conv � 26 years old
students
ELISA 59 72.9
Corona, 2010
[28]
2002–05 Mexico Community CS Conv 21–25 years old
students
ELISA 412 59.7
Corona, 2010
[28]
2002–05 Mexico Community CS Conv 18–20 years old
students
ELISA 335 50.1
Cowan, 2003
[45]
- Brazil Outpatient
clinic
CS Conv 15–19 years old
adults
ELISA 146 83.3
Cowan, 2003
[45]
- Brazil Outpatient
clinic
CS Conv 20–29 years old
adults
ELISA 147a 83.6
Cowan, 2003
[45]
- Brazil Outpatient
clinic
CS Conv 30–34 years old
adults
ELISA 147a 95.2
Cowan, 2003
[45]
- Brazil Outpatient
clinic
CS Conv 35–39 years old
adults
ELISA 147a 92.9
Cowan, 2003
[45]
- Brazil Outpatient
clinic
CS Conv 40–44 years old
adults
ELISA 147a 96.0
Cowan, 2003
[45]
- Brazil Outpatient
clinic
CS Conv �45 years old adults ELISA 147a 94.6
De Salles-
Gomes, 1981
[46]
1980 Brazil Outpatient
clinic
CS Conv 15–19 years old
adults
IF 50 90.0
De Salles-
Gomes, 1981
[46]
1980 Brazil Outpatient
clinic
CS Conv 20–24 years old
adults
IF 50 84.0
De Salles-
Gomes, 1981
[46]
1980 Brazil Outpatient
clinic
CS Conv 25–29 years old
adults
IF 50 86.0
De Salles-
Gomes, 1981
[46]
1980 Brazil Outpatient
clinic
CS Conv 30–34 years old
adults
IF 60 98.3
De Salles-
Gomes, 1981
[46]
1980 Brazil Outpatient
clinic
CS Conv 35–39 years old
adults
IF 50 90.0
De Salles-
Gomes, 1981
[46]
1980 Brazil Outpatient
clinic
CS Conv �40 years old adults IF 50 96.0
Evans, 1974
[49]
- Brazil Outpatient
clinic
CCC Conv Healthy adults IF 26 87.5
Jimemez, 1979
[50]
- Costa Rica Outpatient
clinic
CS Conv �18 years old
students
NAb 16 50.0
Levett, 2005
[51]
- Barbados Outpatient
clinic
CS Conv Blood donors ELISA 184 81.0
Levett, 2005
[51]
- Barbados Outpatient
clinic
CS Conv Ante-natal clinic
attendees
ELISA 122 83.6
Lupi, 2011 [52] 1996–97 Brazil Outpatient
clinic
Cohortb Conv Blood donors ELISA 155 68.0
Oberle, 1989
[53]
1984–85 Costa Rica Community CS MCS �25 years old
females
MAb 766 97.1
Patnaik, 2007
[54]
1985–97 Peru Community CS Conv Peruvian women WB 171 91.8
Patnaik, 2007
[54]
1985–97 Colombia Community CS Conv Colombian women WB 65 89.2
(Continued)
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Table 1. (Continued)
Author, year Year(s) of
data
collection
Country Study site Study
design
Sampling
method
Population HSV-1
serological
assay
Sample
size
HSV-1
seroprevalence (%)
Prabhakar, 1984
[55]
- Jamaica Hospital CCC Conv Healthy Jamaican
women
NAb 60 38.3
Smith, 2002
[29]
1996–97 Peru Hospital CCC Conv Healthy Peruvian
women
WB 171 91.8
Smith, 2002
[29]
1985–88 Colombia Community CCC Conv Healthy Colombian
women
WB 65 89.2
Healthy age-mixed populations
(n = 2)
Conde-Glez,
2013 [44]
2005–06 Mexico Community CS RS 10–19 years old
females
ELISA 252 70.0
Conde-Glez,
2013 [44]
2005–06 Mexico Community CS RS 10–19 years old
males
ELISA 264 71.0
Clinical adult populations
(n = 7)
Calderon, 2018
[56]
2014–15 Peru Outpatient
clinic
CS Conv Women with breast
cancer
ELISA 44 88.6
Evans, 1974
[49]
- Brazil Outpatient
clinic
CCC Conv Patients with
Hodgkin’s disease
IF 26 84.4
Moreira, 2018
[57]
2015–16 Brazil Outpatient
clinic
CCC Conv Women from a
highly ZIKV-affected
region
WB 32 93.8
Moreira, 2018
[57]
2015–16 Brazil Outpatient
clinic
CCC Conv Women from a
highly ZIKV-affected
region
WB 160 95.0
Smith, 2002
[29]
1996–97 Peru Hospital CCC Conv Women with
squamous-cell
carcinoma
WB 166 91.5
Smith, 2002
[29]
1996–97 Peru Hospital CCC Conv Women with adeno-
squamous carcinoma
WB 24 100
Smith, 2002
[29]
1985–88 Colombia Hospital CCC Conv Women with
squamous-cell
carcinoma
WB 78 74.4
Other populations (n = 16)
Levett, 2005
[51]
- Barbados Outpatient
clinic
CS Conv HIV-positive adults ELISA 120 89.2
Luchsinger,
2010 [58]
2005–06 Chile Outpatient
clinic
CS Conv HIV-positive adults ELISA 400 92.2
Boulos, 1992
[59]
- Haiti Outpatient
clinic
CS Conv Healthy/clinical
women
ELISA 228 96.9
Conde-Glez,
1999 [60]
1992 Mexico Outpatient
clinic
CS Conv 16–22 years old
FSWs
WB 302 92.7
Conde-Glez,
1999 [60]
1992 Mexico Outpatient
clinic
CS Conv 23–27 years old
FSWs
WB 330 93.1
Conde-Glez,
1999 [60]
1992 Mexico Outpatient
clinic
CS Conv 28–32 years old
FSWs
WB 187 94.7
Conde-Glez,
1999 [60]
1992 Mexico Outpatient
clinic
CS Conv 33–37 years old
FSWs
WB 101 94.1
Conde-Glez,
1999 [60]
1992 Mexico Outpatient
clinic
CS Conv >37 years old FSWs WB 77 100
Duenas, 1972
[61]
- Colombia Outpatient
clinic
CS Conv 14–15 years old
FSWs
NAb 15 100
(Continued)
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The second model included age group, sex, population type, and year of publication. It
explained 69.57% of the seroprevalence variation. Compared to those aged�10, seropreva-
lence was 1.36-fold (95% CI: 1.19–1.56) higher in those aged 10–20, 1.44-fold (95% CI: 1.25–
1.65) higher in those aged 20–30, 1.70-fold (95% CI: 1.47–1.97) higher in those aged 30–40,
and 1.81-fold (95% CI: 1.58–2.08) higher in those aged�40. There was evidence here for a sta-
tistically-significant declining seroprevalence over time by 0.99-fold (95% CI: 0.99–0.99) per
year, in contrast to the first model analysis (Table 3) and the analyses including the year of
publication as a category (S3 Table), where the evidence for the decline in sero-prevalence did
not reach statistical significance.
HSV-1 virus isolation in genital ulcer disease and in genital herpes
Tables 4 and 5 summarize the extracted proportions of HSV-1 virus isolation in GUD (n = 5)
and in genital herpes (n = 9), as well as their pooled mean estimates.
In GUD cases, the virus isolation proportion ranged between 0.0–6.6%, with a median of
1.1% and a pooled mean of 0.9% (95% CI: 0.0–3.6%). In genital herpes cases, the proportion
ranged between 0.0–28.5%, with a median of 10.0% and a pooled mean of 10.9% (95% CI: 4.4–
19.4%). Both meta-analyses of proportions showed strong evidence of heterogeneity (Table 5).
Forest plots can be found in S2 Fig.
Quality assessment
A total of 31 reports were included in the systematic review, while an additional 12 reports
were excluded due to potential issues in their diagnostic method (Fig 2).
Table 1. (Continued)
Author, year Year(s) of
data
collection
Country Study site Study
design
Sampling
method
Population HSV-1
serological
assay
Sample
size
HSV-1
seroprevalence (%)
Duenas, 1972
[61]
- Colombia Outpatient
clinic
CS Conv 16–17 years old
FSWs
NAb 56 100
Duenas, 1972
[61]
- Colombia Outpatient
clinic
CS Conv 18–19 years old
FSWs
NAb 43 100
Duenas, 1972
[61]
- Colombia Outpatient
clinic
CS Conv 20–21 years old
FSWs
NAb 34 100
Duenas, 1972
[61]
- Colombia Outpatient
clinic
CS Conv 22–25 years old
FSWs
NAb 46 100
Duenas, 1972
[61]
- Colombia Outpatient
clinic
CS Conv 26–35 years old
FSWs
NAb 95 100
Duenas, 1972
[61]
- Colombia Outpatient
clinic
CS Conv �36 years old FSWs NAb 54 100
Lupi, 2011 [52] 1996–97 Brazil Hospital Cohortb Conv Men who have sex
with men
ELISA 170 85.0
a Study included sample size only for the total sample, but not for the strata. Each stratum sample size was set at total sample size divided by the number of strata.
b The original study design of the study is prospective cohort. The included seroprevalence measures are those for the baseline measures at the onset of the study, before
start of follow-up.
c The original study design of the study is case-control. The included seroprevalence measures are those for each of cases and controls, separately. The population type
classification was assigned based on the actual population type for each of cases and controls, separately.
Abbreviations: Conv = Convenience, CS = Cross-sectional, CC = Case-control, ELISA = Enzyme-linked immunosorbent type-specific assay, FSWs = Female sex
workers, HIV = Human immunodeficiency virus, HSV-1 = Herpes simplex virus type 1, IF = Indirect immunofluorescence, MAb = Monoclonal antibody,
MCS = Multistage cluster sampling, NAb = Neutralizing antibody, RS = Random sampling, WB = Western blot, ZIKV = Zika virus.
https://doi.org/10.1371/journal.pone.0215487.t001
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Table 2. Pooled mean estimates for HSV-1 seroprevalence in Latin America and the Caribbean.
Population type Outcome
measures
Samples HSV-1
seroprevalence
Pooled mean HSV-1
seroprevalence
Heterogeneity measures
Total
n
Total
N
Range Median Mean
(95% CI)
Qa
(p-value)
I2b (%)
(95% CI)
Predictionc Interval
(%)
Healthy general populations
Children 19 2,026 7.7–92.0 55.1 57.2 (49.7–64.6) 190.8 (p<0.001) 90.6 (86.8–
93.3)
24.7–86.7
Adults 51 7,917 38.3–98.9 87.6 84.5 (79.9–88.5) 1,323.5
(p<0.001)
96.2 (95.7–
96.8)
46.1–100
Age-mixed 2 516 70.0–71.0 70.5 70.3 (66.2–74.2) d - - -
All healthy general populations 72 10,459 7.7–98.9 81.0 77.7 (72.9–82.2) 2,269.1
(p<0.001)
96.9 (96.5–
97.3)
32.6–100
Clinical populations
Adults 7 530 74.4–100 91.5 90.9 (84.2–95.9) 25.9 (p<0.001) 76.8 (51.5–
88.9)
65.5–100
All clinical populations 7 530 74.4–100 91.5 90.9 (84.2–95.9) 25.9 (p<0.001) 76.8 (51.5–88.9 65.5–100
Other populations
HIV positive patients 2 520 89.2–92.2 90.7 91.5 (88.8–93.7)d - - -
Female sex workers 12 1,340 93.1–100 100 98.5 (96.4–99.8) 46.3 (p<0.001) 76.2 (58.4–
96.4)
88.4–100
Men who have sex with men 1 170 - - 85.3 (79.1–90.2)d - - -
Mixed healthy/clinical adults
populations
1 228 - - 96.9 (93.8–98.7)d - - -
Age group
�10 years 14 1,438 7.7–76.0 50.5 49.7 (42.8–56.6) 76.4 (p<0.001) 83.0 (72.7–
89.4)
24.8–74.7
10–20 years 17 2,294 46.6–100 74.6 77.8 (67.9–84.8) 280.8 (p<0.001) 94.3 (92.2–
95.8)
40.0–99.5
20–30 years 12 1,926 53.6–100 82.5 82.8 (73.1–90.8) 276.9 (p<0.001) 96.0 (94.5–
97.2)
39.1–100
30–40 years 9 1,181 81.7–98.3 92.9 92.5 (89.4–95.1) 24.6 (p = 0.002) 67.4 (34.3–
83.8)
81.4–99.0
�40 years 11 2,128 89.2–98.0 94.6 94.2 (92.7–95.5) 17.5 (p = 0.064) 42.9 (0.0–71.8) 89.9–97.4
Mixed 32 4,280 38.3–100 90.3 89.6 (85.7–93.9) 405.7 (p<0.001) 92.4 (90.2–
94.0)
62.9–100
Age bracket
All children 19 2,026 7.7–92.0 55.1 57.2 (49.7–64.6) 190.8 (p<0.001) 90.6 (86.8–
93.3)
24.7–86.7
All adults 73 10,690 38.3–100 91.0 88.4 (85.2–91.2) 1,588.2
(p<0.001)
95.5 (94.8–
96.0)
54.8–100
All age-mixed 3 531 70.0–100 71.0 77.5 (65.8–87.5) 12.3 (p = 0.002) 83.7 (50.8–
94.6)
0.0–100
Year of publication category
<2000 28 2,935 7.7–100 93.6 90.8 (85.8–94.9) 394.7 (p<0.001) 93.2 (91.2–
94.7)
57.1–100
2000–2009 32 3,844 29.0–100 83.0 80.7 (73.6–87.0) 847.7 (p<0.001) 96.3 (95.6–
97.0)
34.0–100
2010–2018 35 6,468 38.3–98.0 78.0 78.8 (72.7–84.3) 1,113.4
(p<0.001)
96.9 (96.4–
97.4)
37.4–100
All studies 95 13,335 7.7–100 86.0 83.1 (79.3–86.5) 2,772.4
(p<0.001)
96.6 (96.2–
97.0)
40.2–100
a Q: The Cochran’s Q statistic is a measure assessing the existence of heterogeneity in pooled outcome measures, here HSV-1 seroprevalence.
b I2: A measure assessing the magnitude of between-study variation that is due to true differences in HSV-1 seroprevalence across studies rather than sampling variation.
c Prediction interval: A measure quantifying the distribution 95% interval of true HSV-1 seroprevalence around the estimated pooled mean.
d No meta-analysis was done as number of studies was <3. If there was only one study, the reported 95% CI is the 95% CI of this study. If there were two studies, both
samples were merged to yield one sample size, for which the 95% CI was calculated.
Abbreviations: CI = Confidence interval, HIV = Human immunodeficiency virus, HSV-1 = Herpes simplex virus type 1.
https://doi.org/10.1371/journal.pone.0215487.t002
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Summary of the precision and ROB assessments are in S4 Table. High precision was found
in the majority of studies (62.9%). High ROB in the sampling method domain was found in
the vast majority of studies (94.3%). Low ROB in the response rate domain was found in 25.7%
of studies, while the remaining studies had a high ROB (2.9%), or an unclear ROB (71.4%).
Table 3. Univariable and multivariable meta-regression models for HSV-1 seroprevalence in Latin America and the Caribbean.
Outcome
measures
Samples Univariable analysis Multivariable analysisa
Model 1a Model 2b
Total n Total N RR (95%CI) p-value Adjusted R2
(%)
ARR (95%CI) p-value ARR (95%CI) p-value
Population
Characteristics
Age bracket Children 19 2,026 1.00 - 1.00 - - -
Adults 73 10,690 1.45 (1.29–1.64) <0.001 1.39 (1.24–1.57) <0.001 - -
Age-mixed 3 531 1.35 (1.04–1.75) 0.022 35.37 1.30 (1.00–1.67) 0.042 - -
Age group �10 14 1,438 1.00 - - - 1.00 -
10–20 17 2,294 1.44 (1.24–1.67) <0.001 - - 1.36 (1.19–1.56) <0.001
20–30 12 1,926 1.53 (1.31–1.79) <0.001 - - 1.44 (1.25–1.65) <0.001
30–40 9 1,181 1.76 (1.49–2.08) <0.001 - - 1.70 (1.47–1.97) <0.001
�40 11 2,128 1.81 (1.54–2.11) <0.001 - - 1.81 (1.58–2.08) <0.001
Mixed 32 4,280 1.68 (1.47–1.93) <0.001 53.99 - - 1.54 (1.35–1.75) <0.001
Sex Female 46 6,723 1.00 - 1.00 - 1.00 -
Male 17 2,771 0.86 (0.75–1.00) 0.053 0.96 (0.85–1.09) 0.572 0.97 (0.88–1.07) 0.557
Mixed 32 3,751 0.93 (0.82–1.05) 0.277 3.62 1.03 (0.92–1.14) 0.618 1.00 (0.92–1.09) 0.956
Population type Healthy 72 10,456 1.00 - 1.00 - 1.00 -
Clinical 7 530 1.19 (0.99–1.43) 0.062 1.10 (0.93–1.29) 0.249 1.12 (0.97–1.28) 0.116
Other 16 2,258 1.28 (1.12–1.45) <0.001 17.13 1.15 (1.01–1.31) 0.035 1.16 (1.04–1.29) 0.006
Country’s income UMIC 85 11,891 1.00 - - - - -
HIC 5 925 1.12 (0.88–1.42) 0.324 - - - -
Otherc 5 429 0.95 (0.73–1.22) 0.665 0.00 - - - -
Study methodology
characteristics
Assay type Western blot 27 3,029 1.00 - - - - -
ELISA 46 8,508 0.93 (0.82–1.05) 0.277 - - - -
Others 22 1,710 1.05 (0.90–1.22) 0.496 4.83 - - - -
Sample sized <100 13 791 1.00 - - - - -
�100 82 12,454 0.93 (0.75–1.08) 0.364 0.26 - - - -
Sampling method Non-
probability-
based
69 8,536 1.00 - - - - -
Probability-
based
26 4,701 0.93 (0.82–1.45) 0.210 1.41 - - - -
Response rate �80 22 5,155 1.00 - - - - -
Otherwisee 73 8,091 0.91 (0.80–1.03) 0.164 0.93 - - - -
Temporal measures Year of
publication
category
<2000 28 2,935 1.00 - - - - -
2000–2009 32 3,844 0.87 (0.76–0.91) 0.053 - - - -
2010–2018 35 6,468 0.86 (0.75–0.70) 0.023 8.67 - - - -
Year of data collection 95 13,335 0.99 (0.99–1.00) 0.047 6.86 - - - -
Year of publication 95 13,335 0.99 (0.99–0.99) 0.035 7.66 0.99 (0.99–1.00) 0.389 0.99 (0.99–0.99) 0.043
a Variance explained by the final multivariable model 1 (adjusted R2) = 42.82%.
b Variance explained by the final multivariable model 2 (adjusted R2) = 69.57%.
c Other includes one measure of a low income country (Haiti) and the measures extracted from studies including different countries.
d Sample size denotes the sample size of the study population found in the original publication.
e Otherwise indicates either response rate was <80% or response rate not included in the report.
Abbreviations: ARR = Adjusted risk ratio, CI = Confidence interval, ELISA = Enzyme-linked immunosorbent type-specific assay, HIC = High-income country, HSV-
1 = Herpes simplex virus type 1, RR = Risk ratio, UMIC = Upper-middle-income country.
https://doi.org/10.1371/journal.pone.0215487.t003
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Since none of the study characteristics of sample size, sampling method, and response rate
were found associated with HSV-1 seroprevalence (Table 3), it is not likely that precision nor
ROB have affected the results of the present study.
Discussion
The systematic review and meta-analytics reported here indicate that HSV-1 infection is
widely prevalent in Latin America and the Caribbean, at a seroprevalence level that is higher
than that of the global population at 67% [1]. Nearly 60% of children and 90% of adults are
infected, a higher seroprevalence than that in Western Countries [31] and Asia [8], though
lower than that in Africa [32] and the Middle East and North Africa (MENA) [33]. Seropreva-
lence increased steadily with age, but most HSV-1 acquisitions still occurred in childhood
(Tables 2 and 3).
Table 4. Studies reporting proportions of HSV-1 virus isolation in clinically-diagnosed GUD and in clinically-diagnosed genital herpes in Latin America and the
Caribbean.
Author, year Year(s) of data
collection
Country Study site Study
design
Sampling
method
Population HSV-1
biological
assay
Sample
size
Proportion of HSV-
1 isolation (%)
HSV-1 virus isolation in clinically-diagnosed GUD (n = 5)
Gomes Naveca,
2013 [62]
2008 Brazil Outpatient
clinic
CS Conv Patients with GUD PCR 15 6.6
Gomes Naveca,
2013 [62]
2008 Brazil Outpatient
clinic
CS Conv Patients with
primary GUD
PCR 324 4.0
Gomes Naveca,
2013 [62]
2008 Brazil Outpatient
clinic
CS Conv Patients with
recurrent GUD
PCR 95 1.1
Noda, 2016 [63] 2012 Cuba Outpatient
clinic
CS Conv Men with GUD PCR 113 0.0
Valdespino-Gomez,
1995 [64]
1990 Mexico Community CS Conv FSWs with genital
ulcers
IFA 71 0.0
HSV-1 virus isolation in clinically-diagnosed genital herpes (n = 9)
Balachandran, 1982
[27]
- Puerto
Ricco
Outpatient
clinic
CS Conv STI clinic attendees IFA 12 8.3
Belli, 1990 [65] 1982–83 Argentina Outpatient
clinic
CS Conv Patients with genital
herpes
IFA 25 20.0
Do Nascimento,
1998 [30]
1995 Brazil Outpatient
clinic
CS Conv HIV patients with
genital herpes
PCR 36 5.0
Hun,1987 [66] - Costa Rica Outpatient
clinic
CS Conv STI clinic attendees Culture 12 25.0
Prabhakar, 1987
[67]
1982 Jamaica Outpatient
clinic
CS Conv STI clinic attendees IFA 40 0.0
Schultz, 1994 [68] 1988 Chile Outpatient
clinic
CS Conv Pregnant women
with genital herpes
DFA 20 10.0
Suarez, 1988 [69] 1985 Chile Outpatient
clinic
CS Conv Patients with
primary genital
herpes
IFA 14 28.5
Suarez, 1988 [69] 1985 Chile Outpatient
clinic
CS Conv Patients with
recurrent genital
herpes
IFA 61 9.8
Suarez, 1989 [70] 1984 Chile Outpatient
clinic
CS Conv Women with genital
herpes
DFA 13 23.1
Abbreviations: Conv = Convenience, CS = Cross sectional, DFA = Direct fluorescent assay, FSWs = Female sex workers, GUD = Genital ulcer disease, HSV-1 = Herpes
simplex virus type 1, IFA = Indirect immunofluorescence assay, PCR = Polymerase chain reaction, RS = Random Sampling, STI = Sexually transmitted infection.
https://doi.org/10.1371/journal.pone.0215487.t004
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Age was by far the strongest predictor of infection, explaining alone>50% of the seropreva-
lence variation (Table 3). Meanwhile, sex, clinical condition, and country’s income did not
affect HSV-1 seroprevalence (Table 3), in broad agreement with the results of similar studies
for Africa [32], Asia [8], and MENA [33]. These findings affirm the notion that HSV-1 is a
truly general population infection, with largely homogenous exposure risk in the population.
There was evidence for a declining seroprevalence over the last three decades, but the exact
effect size of the decline and nature of the decline (linear or not) are not yet certain with cur-
rently available data (Tables 2 and 3 and S3 Table). While seroprevalence declines have been
also observed in North America and Europe [31, 34–41], no evidence for such declines was
found in Africa [32], Asia [8], and MENA [33]. The large gap in HSV-1 seroprevalence
between children and adults (Tables 2 and 3), supports also the interpretation of recent
declines in seroprevalence, with the currently older cohorts experiencing higher infection risk
in earlier times. As observed in North America [31], improvements in hygiene and standard of
living may have driven the seroprevalence declines.
With this evidence for a possible slow transition in HSV-1 epidemiology in Latin America
and the Caribbean, there is a cause for concern for genital herpes, as increasingly a larger frac-
tion of adolescents may initiate sexual activity with no antibodies to protect them against
acquiring HSV-1 sexually, and thus at risk of genital herpes. Indeed, we found evidence sup-
porting a role for HSV-1 as the etiological cause of genital herpes (Tables 4 and 5), though at
rates much lower than those observed in Western countries [4, 5, 7, 9–11] and Asia [8].
This study has limitations. Data were available only for 14 mostly populous countries
(Tables 1 and 4), with no data found for the remaining 32 smaller countries. Studies varied in
methods and quality and used different diagnostic assays, with potentially different sensitivity
and specificity profiles [16, 17]. However, no effect was found on seroprevalence for assay
type, sample size, sampling method, and response rate (Table 3), indicating that the variability
in study methods may not have impacted the results and findings of the present study.
Conclusions
As in North America, Europe, and Asia [5, 7–11, 31, 35, 42], there is evidence for a possible
transitioning HSV-1 epidemiology in Latin America and the Caribbean, though at a slower
rate and with still limited contribution for HSV-1 in genital herpes and as a sexually transmit-
ted infection. HSV-1 seroprevalence appears to be declining, with the younger cohorts
Table 5. Pooled proportions of HSV-1 virus isolation in clinically-diagnosed GUD and in clinically-diagnosed genital herpes in Latin America and the Caribbean.
Population type Outcome
measures
Samples Proportion of
HSV-1 isolation
(%)
Pooled proportion of HSV-1
isolation (%)
Heterogeneity measures
Total
n
Total
N
Range Median Mean
(95% CI)
Qa
(p-value)
I2b (%)
(95% CI)
Prediction
Intervalc (%)
Patients with clinically-
diagnosed GUD
5 618 0.0–6.6 1.1 0.9 (0.0–3.6) 12.9
(p = 0.0116)
69.1 (20.7–
88.0)
0.0–14.6
Patients with clinically-
diagnosed genital herpes
9 233 0.0–
28.5
10.0 10.9 (4.4–19.4) 21.1
(p = 0.0069)
62.1 (21.7–
81.6)
0.0–40.4
a Q: The Cochran’s Q statistic is a measure assessing the existence of heterogeneity in pooled outcome measures, here proportions of HSV-1 virus isolation.
b I2: A measure assessing the magnitude of between-study variation that is due to true differences in proportions of HSV-1 virus isolation across studies rather than
sampling variation.
c Prediction interval: A measure quantifying the distribution 95% interval of true proportions of HSV-1 virus isolation around the estimated pooled mean.
Abbreviations: CI = Confidence interval, GUD = Genital ulcer disease, HSV-1 = Herpes simplex virus type 1.
https://doi.org/10.1371/journal.pone.0215487.t005
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experiencing lower infection risk than those experienced by the younger cohorts in earlier
times. Yet, HSV-1 persists as a widely prevalent infection in this region, with 60% of children
and 90% of adults being infected. These findings support the need for surveillance to monitor
trends in seroprevalence and genital herpes etiology, and highlight the need for a vaccine to
prevent infection and associated disease burden.
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